Novo Nordisk down as it warns about pricing pressure in the USA

1 November 2017

Danish diabetes giant Novo Nordisk (NOV: N) saw its shares dip 2.9% to 308.50 Danish kroner this morning, after the company warned that draft legislation in some US states to make pricing more transparent could impact business in its largest market, and forecast only modest growth for the full years 2017 and 2018.

Novo Nordisk reported that, for the first nine months of 2017, sales increased 2% to 83.7 billion kroner ($13.08 billion), a rise of 3% in local currencies.

Operating profit rose 5% reported in Danish kroner and by 6% in local currencies to 38.9 billion kroner. Net profit increased 2% to 29.9 billion kroner. Diluted earnings per share for the nine months were up 5% to 12.03 kroner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK